

OBIS Strategic Investment Series 2027

A comprehensive architecture for investment, valuation, intellectual property, financing and collaboration.

An out-of-the-ordinary series

Designed to strengthen OBIS's financing process and strategic management in its early stage, this series organizes — in a single, logical and coherent system — the investment thesis, priority programs, valuation, capital structure, intellectual property protection and the institutional collaboration framework.



10
integrated
documents

A modular and coherent series providing a complete view for investors.



LPS™ and SPI™
as quantified
value anchors

A commercial platform and strategic model with explicit metrics and value scenarios.



72
proposed products
across six
generations

A biotechnology platform with broad market architecture and multi-sector potential (2027–2034).



Seed round
objective:
US\$1.2M

To advance the platform development, priority programs and clinical and regulatory validation.



**Pre-Money
Valuation**
(current standard):
US\$5.448B

Derived from the OBIS financial model, documented assumptions and explicit valuation methodology (2027–2034).



**Intellectual property,
milestones and
value inflection**

An integrated strategy for IP, development milestones and key value catalysts.

**From concept to structure.
From vision to execution.**